LEXINGTON, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the Company will be presenting at the Piper Jaffray 23rd Annual Healthcare Conference at 2:30 p.m. EST on November 30, 2011, in New York City.
Piper Jaffray is using an “unplugged” fireside chat format for the presentation sessions. Dan Passeri, Curis’ President and Chief Executive Officer, will provide a brief overview of Curis’ business strategy and pipeline of small molecule targeted cancer drug candidates, after which a Piper Jaffray equity analyst will moderate a question and answer session.
There will be a corresponding audio webcast of the presentation, which can be accessed by visiting:
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=CRIS&item_id=4229188
The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at www.curis.com.